Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Operator

Hello, and welcome to the Taysha Gene Therapies Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.

It is now my pleasure to introduce Vice President of Corporate Communications and Investor Relations, Hayleigh Collins.

Hayleigh Collins
Director of Corporate Communications & Investor Relations

Thank you. Good afternoon, and welcome to Taysha’s second quarter 2026 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of this press release is available on the company’s website and through our SEC filings.

Joining me on today’s call are Sean Nolan, Taysha’s Chief Executive Officer, Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.

On today’s call, we will be making forward-looking statements, including statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the